Susceptibility testing and clinical outcome in fungal keratitis

British Journal of Ophthalmology

Volumn 94, Issue 3, 2010, Pages 384-385

  Shapiro, Brett L ^a   Lalitha, Prajna ^b   Loh, Allison R ^a,c   Fothergill, Annette W ^d   Prajna, Namperumalsamy V ^b   Srinivasan, Muthiah ^b   Kabra, Amit ^b   Chidambaram, Jaya ^a   Acharya, Nisha R ^a   Lietman, Thomas M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Aravind Eye Hospitals   (India)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPLEGIC AGENT; NATAMYCIN;

ACREMONIUM; ANTIFUNGAL SUSCEPTIBILITY; ASPERGILLUS FLAVUS; ASPERGILLUS FUMIGATUS; ASPERGILLUS NIGER; ASPERGILLUS TERREUS; BROTH DILUTION; CURVULARIA; DRECHSLERA; EPITHELIZATION; FUNGUS; FUNGUS ISOLATION; FUSARIUM; HOSPITALIZATION; HUMAN; KERATOMYCOSIS; LETTER; MAJOR CLINICAL STUDY; MINIMUM INHIBITORY CONCENTRATION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

ANTIFUNGAL AGENTS; CORNEAL ULCER; EYE INFECTIONS, FUNGAL; HUMANS; MICROBIAL SENSITIVITY TESTS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 77949527488     PISSN: 00071161     EISSN: 14682079     Source Type: Journal    
DOI: 10.1136/bjo.2009.158675     Document Type: Letter

References (10)

1. Rex JH, Pfaller MA. Has antifungal susceptibility testing come of age? Clin Infect Dis 2002;35:982e9.
2. Lalitha P, Prajna NV, Kabra A, et al. Risk factors for treatment outcome in fungal keratitis. Ophthalmologica 2006;113:526e30.
3. Lalitha P, Shapiro B, Srinivasan M, et al. Antimicrobial susceptibility of Fusarium, Aspergillus and other filamentous fungi isolated from keratitis. Arch Ophthalmol 2007;125:789e93.
4. Rex JH, Alexander BD, Andes D, et al. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi, approved standard. 2nd edn. (M38eA2). Wayne, PA, USA: Clinical and Laboratory Standards Institute (CLSI), 2008;28:16.
5. Lalitha P, Vijaykumar R, Prajna NV, et al. In vitro natamycin susceptibility of ocular isolates of Fusarium and Aspergillus species: comparison of commercially formulated natamycin eye drops to pharmaceutical-grade powder. J Clin Microbiol 2008;46:3477e8.
6. Chen A, Lalitha P, Srinivasan M, et al. Does in vitro susceptibility predict clinical outcome in bacterial keratitis? Am J Ophthalmol 2007;145:409e12.
7. Wilhelmus KR, Abshire RL, Schlech BA. Influence of fluoroquinolone susceptibility on the therapeutic response of fluoroquinolone-treated bacterial keratitis. Arch Ophthalmol 2003;121:1229e33.
8. Thomas PA, Abraham DJ, Kalavathy CM, et al. Oral itraconazole therapy for mycotic keratitis. Mycoses 1988;31:271e9.
9. O'Day DM, Ray WA, Robinson RD, et al. Correlation of in vitro and in vivo susceptibility of Candida albicans to amphotericin B and natamycin. Invest Ophthalmol Vis Sci 1987:28:596e603.
10. Marangon FB, Miller D, Giaconi JA, et al. In vitro investigation of voriconazole susceptibility for keratitis and endophthalmitis fungal pathogens. Am J Ophthalmol 2004;137:820e5.